PT  - JOURNAL ARTICLE
AU  - Hubert Blain
AU  - Edouard Tuaillon
AU  - Amandine Pisoni
AU  - Laure Soriteau
AU  - Elodie Million
AU  - Marie-Suzanne Léglise
AU  - Isabelle Bussereau
AU  - Stéphanie Miot
AU  - Yves Rolland
AU  - Marie-Christine Picot
AU  - Jean Bousquet
TI  - Prior Covid-19 and high RBD-IgG levels correlate with protection against VOC-δ SARS-CoV-2 infection in vaccinated nursing home residents
AID  - 10.1101/2021.09.21.21263880
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.21.21263880
4099  - http://medrxiv.org/content/early/2021/09/21/2021.09.21.21263880.short
4100  - http://medrxiv.org/content/early/2021/09/21/2021.09.21.21263880.full
AB  - Background Nursing Home (NH) residents are at high risk of serious illness and death from coronavirus disease 2019 (Covid-19), especially with the SARS-CoV-2 variants of concerns (VOC). It is unknown as to whether a history of Covid-19 prior to the vaccine and post-vaccine RBD-IgG levels are predictors of BNT162b2 vaccine effectiveness against VOC–δ in nursing home residents.Methods We analyzed the data from two NHs that faced a VOC-δ outbreak in July-August 2021. These NHs had suffered prior Covid-19 outbreaks in 2020 and 2021. In many of the residents, RBD-IgG levels were measured 6 weeks after the second vaccine dose, i.e. 3 to 5 months before the VOC-δ outbreak onset, and again during the outbreak (SARS-CoV-2 IgG II Quant assay, Abbott Diagnostics). We compared residents with vs without prior Covid-19 for (i) VOC-δ incidence, (ii) the correlation between post-vaccine RBD-IgG levels and VOC-δ incidence, and (iii) the time-related change in RBD-IgG levels.Results Among the 140 analyzed residents (58 to 101 years; 94 females, 46 men, mean age: 84.6 yr ± 9.5 yr), one resident among the 44 with prior Covid-19 before vaccination developed a VOC-δ infection during the outbreak (1.3%) vs 55 of the 96 without Covid-19 prior to vaccination (57.3 %)(p<0.0001). The median value for RBD-IgG 6 weeks after the vaccine and during the outbreak was higher in residents with prior Covid-19 (31,553 AU/mL and 22,880 AU/mL) than in those without (1,050 AU/mL and 260 AU/mL)(p<0.0001). In residents without Covid-19 prior to vaccination, post-vaccination RDB-IgG levels did not predict protection against VOC-δ infection.Conclusions In contrary to residents with prior SARS-CoV-2 infection, those without a history of Covid-19 before two BNT162b2 doses are not protected against VOC-δ infection and their RBD-Ig-G levels are low 3 to 5 months after vaccination. This suggests that a booster vaccine dose should be considered in this group of residents for a better protection against VOC-δ infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was not supported by a grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Anonymized clinical and biological data were analyzed in accordance with the Montpellier University Hospital institutional review board approval (IRB-MTP _2021_04_202000534).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available on request at the following address: h-blain{at}chu-montpellier.fr